RecruitingPhase 3NCT06747351
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- TAK-881(biological)
- Enrollment
- 59 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- HonorHealth Neurology, Scottsdale, Arizona, United States
- Stanford Neuroscience Health Center, Palo Alto, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Neurology Associates, Maitland, Florida, United States
- Knight Neurology, Rockledge, Florida, United States
- The Washington University, St Louis, Missouri, United States
- NYU Langone Health, New York, New York, United States
- University of North Carolina (UNC), Chapel Hill, North Carolina, United States
- Duke University Hospital, Durham, North Carolina, United States
- Raleigh Neurology Associates, Raleigh, North Carolina, United States
- Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic - Marquam Hill, Portland, Oregon, United States
- Neurology Rare Disease Center, Denton, Texas, United States
- The University of Vermont Medical Center, Burlington, Vermont, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Takeda Development Center Americas, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06747351 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →